Why the patellofemoral compartment needs its own injection thinking

Knee injections are just as relevant when arthritis affects the patellofemoral compartment as when it affects the tibiofemoral joint — but the two situations are not identical, and the distinction shapes which injection is most appropriate.

The patellofemoral joint is where the kneecap glides over the groove at the front of the femur. It is a mechanically distinct space from the inner and outer knee, loaded differently and approached differently during injection. Symptoms of patellofemoral arthritis — aching at the front of the knee, worsened on stairs, prolonged sitting, or deep squatting — differ from the medial compartment pain that most patients picture when they think of "knee OA". Because the compartment is anatomically specific, ultrasound guidance is used when injecting it, to confirm the needle reaches the right space rather than the adjacent tibiofemoral joint.

What injections can achieve here is also worth framing honestly from the outset. None of the available options — whether a corticosteroid, a hyaluronic acid preparation, or a biologic — reverses cartilage loss that has already occurred. Their value lies in reducing pain enough for patients to engage with physiotherapy, manage load effectively, and either delay or avoid surgery. They are bridges, not repairs. The sections below look at each option in turn, drawing on trials and series conducted specifically in patellofemoral osteoarthritis where these exist.

Corticosteroids and hyaluronic acid: the first-line pair

When the question is which injection to start with, the practical answer turns on timing more than mechanism. A corticosteroid works faster; hyaluronic acid (HA) is the better-suited option when the aim is sustained relief over months or when injections are likely to be repeated.

The clearest evidence comes from a 2025 double-blind randomised controlled trial of 60 patients with isolated patellofemoral osteoarthritis, comparing a single intra-articular injection of 2% sodium hyaluronate against triamcinolone acetonide. Both groups showed statistically significant improvement in pain (VAS) and knee function (Kujala score) beginning as early as 48 hours after injection and sustained through six months — the endpoint of the trial. At six months, the two treatments performed equivalently.

The meaningful difference appeared in the first week. The corticosteroid group reported roughly 10 points less pain on a 100-point scale at 48 hours, 72 hours, and one week after injection — a clinically noticeable margin when someone is struggling through daily activities or unable to sleep comfortably. That speed advantage makes corticosteroid the preferred choice when an acute flare is driving the consultation.

The trade-off is frequency. Repeated corticosteroid injections carry a recognised risk of accelerating the cartilage degradation they are being used to manage, which is why use is generally limited to around three or four injections per year. For patients who anticipate needing longer-term support — whether because of chronic symptoms or because they are not yet surgical candidates — hyaluronic acid avoids that ceiling. HA takes a few weeks to reach its full effect, but relief can extend to six months or beyond, and there is no equivalent restriction on how often it may be used.

The practical framework is therefore straightforward: corticosteroid for acute flares where rapid relief matters; HA for ongoing, lower-intensity management or where the treatment is likely to recur.

PRP: the option for active patients who have tried the basics

Across five studies examining PRP specifically in patellofemoral arthritis and chondromalacia patella, every study reported clinically meaningful improvements in pain and function — a consistent signal even if the individual trials were small and, in most cases, uncontrolled. Collectively they span a range of patient profiles and follow-up periods extending to at least 12 months, making the direction of effect reasonably reliable, even if precise effect sizes cannot yet be pooled with confidence.

The most patient-relatable data comes from a case-control study of 18 women aged 25–40 with isolated patellofemoral arthritis who had not responded to conservative treatment. A single PRP injection brought their one-year pain scores to a level comparable to matched patients who had succeeded with conservative treatment alone — in other words, PRP appeared to recover the ground that physio alone had not gained, with the authors suggesting it may postpone or remove the need for surgery. The sample is small, and the absence of a randomised design means the finding needs to be held carefully, but it speaks directly to the question patients at this juncture are asking.

The key timing distinction from corticosteroid is worth being explicit about: PRP does not produce immediate relief. The response builds over weeks rather than days, and patients who expect rapid improvement may be disappointed in the first fortnight. The trade-off is durability — in comparative knee OA data, PRP outperforms corticosteroid at three to six months, reversing the early advantage steroids hold in the first four to six weeks.

PRP is not a first-line option. It is most appropriately considered by patients who have completed a structured physiotherapy programme, have ongoing moderate symptoms, and want to avoid or delay surgery. One additional factor to factor in from the outset: PRP is not covered by most insurers in the UK and is typically funded privately, which is a practical consideration alongside the evidence profile.

Regenerative biologics: BMAC and adipose tissue for more advanced disease

For patients who have not found enough relief from corticosteroids, hyaluronic acid, or PRP, two biologic options occupy the next tier: bone marrow aspirate concentrate (BMAC) and microfragmented autologous adipose tissue (mFAT). Both draw on the body's own regenerative cells, and both have been studied specifically in patellofemoral osteoarthritis — though not yet in randomised controlled trials.

BMAC has been evaluated in two studies involving a combined total of approximately 103 patients with symptomatic PFOA refractory to conservative treatment. In the larger series — 96 consecutive patients receiving ultrasound-guided BMAC injection — pain (VAS), disability (WOMAC), and knee function (IKDC) all improved significantly at 12 months. That study also incorporated MRI follow-up: cartilage volume in treated patients was preserved across the observation period, while an untreated comparator group showed a 6.9% loss — a structurally noteworthy finding. It should be read with appropriate caution: the data come from a retrospective series, not a randomised trial, and cartilage volume measurements from a single cohort do not establish disease modification in isolation.

mFAT, delivered alongside arthroscopy in 23 patients with early-to-moderate PFOA, produced improvements in pain (VAS 8.7 to 5.2) and knee function scores that were sustained at a mean follow-up of just over 22 months. The practically relevant finding for patient selection is that outcomes were not significantly affected by age, BMI, or OA grade — a degree of consistency that may widen the candidate population compared with treatments where these variables predict response.

Both options are most appropriately considered by patients with moderate-to-severe disease who have not responded adequately to standard injections and who wish to delay arthroplasty. Because the evidence base currently rests on retrospective case series rather than trial-level data, neither is a routine or NHS-available pathway; they are typically delivered within a specialist private setting, and individual suitability warrants careful clinical assessment.

Polyacrylamide hydrogel: a different mechanism for heavier-load or advanced cases

Polyacrylamide hydrogel (iPAAG, marketed as Arthrosamid) works differently from every other injection covered in this article. Rather than dispersing through the joint fluid and being gradually reabsorbed, it integrates into the synovial membrane — the tissue lining the joint — and persists there as a structural cushion. The practical implication is a potentially longer-lasting mechanical effect, not because the gel is simply more potent than alternatives, but because it is not cleared by normal joint turnover.

The patellofemoral-specific evidence is limited to one published case series, which documented a reduction in bone marrow lesions after a single iPAAG injection in patients with advanced PFOA — a clinically interesting signal, but not yet a replicated or controlled finding. The broader iPAAG evidence base derives from tibiofemoral OA, where longer-term data on pain and function are better established; extrapolation to the patellofemoral compartment is physiologically reasonable but not yet trial-confirmed for this specific indication.

The non-biodegradable nature of the gel may be of particular relevance in heavier-load or structurally compromised presentations where repeated injections are impractical or where earlier tiers have produced insufficient or short-lived benefit. It is not a starting point, and should not be framed as a general alternative to hyaluronic acid or PRP. Appropriately, it sits within a specialist pathway — most relevant to patients with advanced disease who have not achieved adequate relief from corticosteroids, HA, or biologic options, and for whom continued repeat injecting is limited by frequency constraints or diminishing returns.

Matching the right injection to the right patient

The practical question most patients reach this point asking is not "which injection is best?" but "which one is right for me, now?"

If the main problem is an acute flare — significant swelling, pain that has spiked in recent days — a corticosteroid is the appropriate first step. It acts within 48–72 hours and is well suited to getting symptoms under control quickly. It is not a long-term strategy; repeated use is generally capped because of the cartilage-risk concern with frequent dosing.

If the picture is more chronic — persistent aching, stiffness through the day, no acute episode — hyaluronic acid is a reasonable first-line alternative, particularly where sustained improvement over months is the goal rather than rapid rescue.

If first-line injections have been tried and the patient remains symptomatic — and a course of targeted physiotherapy has been completed — PRP is the next logical step, especially for active or younger patients who want to avoid or delay surgery. The key expectation-setting point here is timing: improvement with PRP builds over weeks, not days, and the comparison with corticosteroids flips in PRP's favour at three to six months.

For patients with moderate-to-severe or refractory disease, BMAC and mFAT are available through specialist pathways. The evidence is consistent in direction but rests on case-series data; these are not routine treatments and require individual clinical assessment before proceeding.

iPAAG becomes most relevant where conventional injections have delivered insufficient or short-lived benefit in heavier-load or advanced cases — as a later-tier option, not a starting point.

A note on technique: all of these injections are more accurately placed under ultrasound guidance, which matters because the patellofemoral compartment is anatomically specific and a blind approach may miss it.

Two broader points apply across the whole framework. First, none of these injections — at any tier — reverse established cartilage loss; the goal is pain reduction sufficient to support active rehabilitation. Second, patients with malalignment or an elevated TT-TG distance (a measure of how far the kneecap sits off-centre relative to the trochlear groove) may not get the most from injections alone. Those who fail non-operative management may be better served by tibial tubercle osteotomy or, where disease is severe and refractory, patellofemoral arthroplasty. A specialist assessment is the clearest way to determine which part of this pathway applies to any individual.

1. [1] Intra-articular injection of Bone Marrow Concentrate (BMC) for patellofemoral Osteoarthritis: Preliminary results under US guidance. (2022). https://doi.org/10.1016/j.jvir.2022.10.006 https://doi.org/10.1016/j.jvir.2022.10.006
2. [2] Efficacy of Single Intra-articular 2% Sodium Hyaluronate versus Corticosteroid Injection in Isolated Patellofemoral Osteoarthritis: A Double-Blind RCT. (2025). https://doi.org/10.1016/j.jisako.2025.101038 https://doi.org/10.1016/j.jisako.2025.101038
3. [3] Intra-Articular Injection of Bone Marrow Concentrate for Patellofemoral Osteoarthritis: Preliminary Results Using a New Tibial Endplate Sample Under Ultrasound Guidance. (2025). https://doi.org/10.3390/bioengineering12111150 https://doi.org/10.3390/bioengineering12111150
4. [4] Effectiveness of intra-articular injection of platelet-rich plasma in isolated patellofemoral arthritis. (2022). https://doi.org/10.21203/rs.3.rs-1239613/v1 https://doi.org/10.21203/rs.3.rs-1239613/v1
5. [5] Intraarticular injection of microfragmented adipose tissue plus arthroscopy in isolated primary patellofemoral osteoarthritis. (2022). https://doi.org/10.1186/s10195-022-00628-9 https://doi.org/10.1186/s10195-022-00628-9